Evidence-based use of statins for primary prevention of cardiovascular disease

American Journal of Medicine

Volumn 125, Issue 5, 2012, Pages 440-446

  Minder, C Michael ^a   Blaha, Michael J ^a   Horne, Aaron ^a   Michos, Erin D ^a   Kaul, Sanjay ^b   Blumenthal, Roger S ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Adult Treatment Panel III; Cardiovascular disease; Coronary heart disease; Hydroxy 3 methylglutaryl coenzyme A reductase inhibitor; Primary prevention; Statin

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PLACEBO; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

COST EFFECTIVENESS ANALYSIS; DRUG SAFETY; EVIDENCE BASED MEDICINE; HEART INFARCTION; HUMAN; ISCHEMIC HEART DISEASE; LIVER FAILURE; MORTALITY; PRIMARY PREVENTION; PRIORITY JOURNAL; REVIEW;

CARDIOVASCULAR DISEASES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; RISK FACTORS;

EID: 84859480711     PISSN: 00029343     EISSN: 15557162     Source Type: Journal    
DOI: 10.1016/j.amjmed.2011.11.013     Document Type: Review

References (34)

1. K.K. Ray, S.R. Seshasai, S. Erqou Statins and all-cause mortality in high-risk primary prevention: a meta-analysis of 11 randomized controlled trials involving 65,229 participants Arch Intern Med 170 2010 1024 1031
2. D. Giugliano, K. Esposito Clinical inertia as a clinical safeguard JAMA 305 2011 1591 1592
3. R. Redberg, M. Katz, D. Grady Diagnostic tests: another frontier for less is more: or why talking to your patient is a safe and effective method of reassurance Arch Intern Med 171 2011 619
4. P.A. Heidenreich, J.G. Trogdon, O.A. Khavjou Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association Circulation 123 2011 933 944
5. J.J. Brugts, T. Yetgin, S.E. Hoeks The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials BMJ 338 2009 2376
6. F. Taylor, K. Ward, T.H. Moore Statins for the primary prevention of cardiovascular disease Cochrane Database Syst Rev 1 2011 CD004816
7. E.J. Mills, B. Rachlis, P. Wu, P.J. Devereaux, P. Arora, D. Perri Primary prevention of cardiovascular mortality and events with statin treatments: a network meta-analysis involving more than 65,000 patients J Am Coll Cardiol 52 2008 1769 1781
8. P. Thavendiranathan, A. Bagai, M.A. Brookhart, N.K. Choudhry Primary prevention of cardiovascular diseases with statin therapy: a meta-analysis of randomized controlled trials Arch Intern Med 166 2006 2307 2313
9. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III) JAMA 285 2001 2486 2497
10. S. Kaul, R.P. Morrissey, G.A. Diamond By Jove! What is a clinician to make of JUPITER? Arch Intern Med 170 12 2010 1073 1077
11. P.M. Ridker, J.G. Macfadyen, B.G. Nordestgaard Rosuvastatin for primary prevention among individuals with elevated high-sensitivity C-reactive protein and 5% to 10% and 10% to 20% 10-year risk Implications of the Justification for Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) trial for "intermediate risk" Circ Cardiovasc Qual Outcomes 3 2010 447 452
12. I. Ford, H. Murray, C.J. Packard, J. Shepherd, P.W. Macfarlane, S.M. Cobbe Long-term follow-up of the West of Scotland Coronary Prevention Study N Engl J Med 357 2007 1477 1486
13. P.S. Sever, N.R. Poulter, B. Dahlof The Anglo-Scandinavian Cardiac Outcomes Trial lipid lowering arm: extended observations 2 years after trial closure Eur Heart J 29 2008 499 508
14. D. Steinberg Earlier intervention in the management of hypercholesterolemia: what are we waiting for? J Am Coll Cardiol 56 2010 627 629
15. A. Kashani, C.O. Phillips, J.M. Foody Risks associated with statin therapy: a systematic overview of randomized clinical trials Circulation 114 2006 2788 2797
16. J.R. Downs, M. Clearfield, S. Weis Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS Air Force/Texas Coronary Atherosclerosis Prevention Study JAMA 279 1998 1615 1622
17. K.M. Dale, C.I. Coleman, N.N. Henyan, J. Kluger, C.M. White Statins and cancer risk: a meta-analysis JAMA 295 2006 74 80
18. M.F. Muldoon, S.D. Barger, C.M. Ryan Effects of lovastatin on cognitive function and psychological well-being Am J Med 108 2000 538 546
19. N. Sattar, D. Preiss, H.M. Murray Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials Lancet 375 2010 735 742
20. D.G. Manuel, K. Kwong, P. Tanuseputro Effectiveness and efficiency of different guidelines on statin treatment for preventing deaths from coronary heart disease: modelling study BMJ 332 2006 1419
21. J.J. Brugts, J.W. Deckers Statin prescription in men and women at cardiovascular risk: to whom and when? Curr Opin Cardiol 25 2010 484 489
22. Aspirin for the prevention of cardiovascular disease: U.S. Preventive Services Task Force recommendation statement Ann Intern Med 150 2009 396 404
23. J.S. Berger, M.C. Roncaglioni, F. Avanzini, I. Pangrazzi, G. Tognoni, D.L. Brown Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials JAMA 295 2006 306 313
24. C. Baigent, L. Blackwell, R. Collins Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials Lancet 373 2009 1849 1860
25. J.M. Wright, V.M. Musini First-line drugs for hypertension Cochrane Database Syst Rev 3 2009 CD001841
26. A.V. Chobanian, G.L. Bakris, H.R. Black The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 report JAMA 289 2003 2560 2572
27. M.J. Pletcher, L. Lazar, K. Bibbins-Domingo Comparing impact and cost-effectiveness of primary prevention strategies for lipid-lowering Ann Intern Med 150 2009 243 254
28. L.D. Lazar, M.J. Pletcher, P.G. Coxson, K. Bibbins-Domingo, L. Goldman Cost-effectiveness of statin therapy for primary prevention in a low-cost statin era Circulation 124 2011 146 153
29. A.M. Gotto Jr, S.J. Boccuzzi, J.R. Cook Effect of lovastatin on cardiovascular resource utilization and costs in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS) AFCAPS/TexCAPS Research Group Am J Cardiol 86 2000 1176 1181
30. P. Lindgren, M. Buxton, T. Kahan Cost-effectiveness of atorvastatin for the prevention of coronary and stroke events: an economic analysis of the Anglo-Scandinavian Cardiac Outcomes Trial - lipid-lowering arm (ASCOT-LLA) Eur J Cardiovasc Prev Rehabil 12 2005 29 36
31. J. Caro, W. Klittich, A. McGuire The West of Scotland coronary prevention study: economic benefit analysis of primary prevention with pravastatin BMJ 315 1997 1577 1582
32. J.P. Strong, G.T. Malcom, C.A. McMahan Prevalence and extent of atherosclerosis in adolescents and young adults: implications for prevention from the Pathobiological Determinants of Atherosclerosis in Youth Study JAMA 281 1999 727 735
33. S.E. Nissen, S.J. Nicholls, I. Sipahi Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial JAMA 295 2006 1556 1565
34. G.S. Berenson, S.R. Srinivasan, W. Bao, W.P. Newman 3rd, R.E. Tracy, W.A. Wattigney Association between multiple cardiovascular risk factors and atherosclerosis in children and young adults The Bogalusa Heart Study N Engl J Med 338 1998 1650 1656